Wall Street analysts expect that AC Immune SA (NASDAQ:ACIU) will announce sales of $8.50 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for AC Immune’s earnings, with estimates ranging from $1.51 million to $15.49 million. AC Immune posted sales of $2.03 million in the same quarter last year, which suggests a positive year over year growth rate of 318.7%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, August 14th.
According to Zacks, analysts expect that AC Immune will report full year sales of $120.51 million for the current financial year, with estimates ranging from $60.98 million to $162.67 million. For the next fiscal year, analysts expect that the firm will post sales of $62.40 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for AC Immune.
AC Immune (NASDAQ:ACIU) last posted its quarterly earnings data on Wednesday, May 15th. The company reported $0.84 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.36). AC Immune had a return on equity of 13.80% and a net margin of 29.66%. The company had revenue of $75.28 million for the quarter, compared to analysts’ expectations of $106.81 million.
NASDAQ:ACIU traded down $0.06 during mid-day trading on Friday, reaching $5.09. The company’s stock had a trading volume of 166,655 shares, compared to its average volume of 492,916. AC Immune has a twelve month low of $3.25 and a twelve month high of $17.40. The firm has a market cap of $348.62 million, a price-to-earnings ratio of -6.21 and a beta of 0.01.
A number of large investors have recently modified their holdings of ACIU. Jane Street Group LLC acquired a new position in shares of AC Immune in the 1st quarter valued at about $56,000. Barclays PLC lifted its stake in shares of AC Immune by 726.2% in the 4th quarter. Barclays PLC now owns 6,378 shares of the company’s stock valued at $61,000 after purchasing an additional 5,606 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in shares of AC Immune in the 1st quarter valued at about $76,000. Marshall Wace North America L.P. lifted its stake in shares of AC Immune by 625.8% in the 1st quarter. Marshall Wace North America L.P. now owns 15,836 shares of the company’s stock valued at $80,000 after purchasing an additional 13,654 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of AC Immune in the 3rd quarter valued at about $107,000. 27.80% of the stock is currently owned by hedge funds and other institutional investors.
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Featured Story: Why do companies issue convertible shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.